Intrapartum - Moderate and Severe AnaemiaPhase 3WOMAN-2NCT03475342
World Maternal Antifibrinolytic Trial_2
A Phase 3 study testing Tranexamic Acid in people with Intrapartum - Moderate and Severe Anaemia, run by London School of Hygiene and Tropical Medicine at 41 sites in 4 countries.
Trial summary
Postpartum haemorrhage (PPH) is responsible for about 100,000 maternal deaths every year, almost all of which occur in low and middle income countries. When given within three hours of birth, tranexamic acid reduces deaths due to bleeding in women with PPH by almost one third. Read more about this study
- Who is it for?
- Any age, women only
- Conditions the study is for
- Intrapartum - Moderate and Severe Anaemia
- What is being tested?
- Tranexamic Acid
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 15,068 participants
- Where
- 41 sitesin 4 countries
- Study dates
- 24 Aug 2019to 29 Oct 2023
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Women only
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Women with moderate or severe anaemia (haemoglobin level <100 g/L or packed cell volume <30%) after giving birth vaginally where the responsible clinician is substantially uncertain whether to use TXA
Who cannot join
- Women who are not legally adult (<18 years) and not accompanied by a guardian
- Women with a known allergy to tranexamic acid or its excipients
- Women who experience postpartum haemorrhage before the umbilical cord is cut or clamped.
Trial locations and contacts
41 sites in 4 countries.
41 sites in 4 countries
Pakistan25 sites
Ayub Teaching Hospital (Unit A)
Abbottabad
Ayub Teaching Hospital (Unit C)
Abbottabad
Ayub Teaching Hospital Unit B
Abbottabad
Bahawalpur Victoria Hospital
Bahawalpur
Aziz Bhatti Teaching Hospital
Gujrat
MCH PIMS
Islamabad
Military Hospital
Islamabad
Civil Hospital
Karachi
Jinnah Postgraduate Medical Centre
Karachi
Koohi Goth Hospital
Karachi
Jinnah Hospital
Lahore
Services Hospital
Lahore
Sir Ganga Ram Hospital Unit 1
Lahore
Sir Ganga Ram Hospital Unit 2
Lahore
Sir Ganga Ram Hospital Unit 3
Lahore
Sir Ganga Ram Hospital Unit 4
Lahore
Chandka SMBBMU Sheikh Zaid Woman Hospital Unit 1
Larkana
Chandka SMBBMU Sheikh Zaid Woman Hospital Units 2 & 3
Lārkāna
Nishtar Hospital Unit 1
Multan
Nishtar Hospital Unit 2
Multan Khurd
Nishtar Hospital Unit 3
Multan Khurd
Bolan Medical Centre
Quetta
Benazir Bhutto Shaheed Hospital
Rawalpindi
Federal Government Polyclinic
Rawalpindi
Holy Family Hospital
Rawalpindi
Tanzania8 sites
Mount Meru Regional Referral Hospital
Arusha
Amana Regional Referral Hospital,
Dar es Salaam
Muhimbili National Hospital
Dar es Salaam
Temeke Regional Referral Hospital
Dar es Salaam
Dodoma Regional Referral Hospital
Dodoma
Tumbi Regional Referral Hospital, Kibaha
Kibaha
Mwananyamala Regional Referral Hospital
Kinondoni
Mbeya Zonal Referral Hospital
Mbeya
Nigeria7 sites
Mother & Child Hospital
Akure
University of Medical Sciences Teaching Hospital
Akure
Adeoyo Maternity Hospital
Ibadan
Ilorin General Hospital
Ilorin
Muhammad Abdullahi Wase Specialist Hospital
Kano
Ladoke Akintola University of Technology Teaching Hospital
Ogbomoso
State Hospital
Oyo
About this study
Official title: Tranexamic Acid for the Prevention of Postpartum Bleeding in Women With Anaemia: an International, Randomised, Double-blind, Placebo Controlled Trial.
Postpartum haemorrhage (PPH) is responsible for about 100,000 maternal deaths every year, almost all of which occur in low and middle income countries. When given within three hours of birth, tranexamic acid reduces deaths due to bleeding in women with PPH by almost one third. However, for many women, treatment of PPH is too late to prevent death and severe morbidities. Over one-third of pregnant women in the world are anaemic and many are severely anaemic. We now want to do the WOMAN-2 trial to see if giving tranexamic acid can prevent PPH and other severe outcomes in women with moderate and severe anaemia.
Read the detailed description
Anaemia is a cause and consequence of PPH. A cohort study in Assam, India found that women with moderate or severe anaemia had a greatly increased risk of PPH. Women with moderate anaemia had a 50% increased risk, whereas those with severe anaemia had a ten-fold increased risk of PPH. Anaemic women may be more susceptible to uterine atony due to impaired oxygen transport to the uterus. Anaemic women experience worse outcomes after PPH. An international survey of 275,000 women found that severe maternal outcomes after PPH were nearly three times more common in anaemic than in non-anaemic women. Even moderate bleeding can be life threatening in anaemic women. Excessive bleeding after childbirth worsens maternal anaemia, resulting in a vicious circle of bleeding and adverse outcomes. Fatigue due to anaemia severely limits a mothers' wellbeing and her ability to care for her children. Despite efforts to prevent anaemia, many women labour with perilously low haemoglobin levels
Tranexamic acid (TXA) inhibits fibrinolysis by blocking the lysine binding sites on plasminogen. TXA reduces surgical bleeding and death due to bleeding in trauma patients. The WOMAN trial assessed the effects of TXA in 20,060 women with PPH. When given within three hours of birth, TXA reduced death due to bleeding by nearly one-third (RR=0.69, 95% CI 0.52 to 0.91, p=0.008). However, for many women, treatment is too late to prevent death from PPH. Most PPH deaths occur in the first hours after giving birth and women with anaemia are at greatly increased risk. Whilst there have been some trials of TXA for the prevention of PPH, most have serious flaws and none collected data on maternal health and wellbeing. There is currently no reliable evidence about the effectiveness and safety of TXA for preventing PPH.
The WOMAN-2 trial will determine reliably the effects of TXA in anaemic women who give birth vaginally.
We will also conduct a pre-planned cohort analysis of data from the WOMAN-2 trial to assess the effect of pain control and episiotomy on the risk of post-partum haemorrhage. Adrenaline is a potent stimulus for fibrinolysis. Adrenaline causes the release of tissue plasminogen activator (TPA) from the endothelium. In trauma victims, high adrenaline levels are associated with increased fibrinolysis, decreased clot strength and increased deaths due to bleeding. Childbirth is intensely painful and maternal adrenaline levels are two to six times higher during labour. Maternal adrenaline concentrations peak in the second and third stages of labour but then rapidly return to normal after birth. Pain control can reduce the maternal catecholamine response. We hypothesize that painful procedures such as episiotomy will significantly increase the risk of postpartum haemorrhage and that pain control will reduce the risk of PPH.
The exposures of interest are the presence or absence of pain control during labour and delivery and whether episiotomy was conducted prior to birth. Pain control will be categorised as present or absent but the type of pain control administered during labour will also be described and examined. The types of pain control recorded in the study are epidural, opioids, 'other', or a combination of opioids and other pain control. For the multivariable regression analysis, the pain control variable was converted into a binary variable indicating whether a participant received any pain control or not. Episiotomy will be categorised as present or absent according to the CRF. The main outcome variable will be a clinical diagnosis of PPH (binary: yes/no), defined as an estimated blood loss of more than 500 mL or any blood loss sufficient to compromise haemodynamic stability within 24 hours. Potential confounding factors will include maternal age, BMI, anaemia, history of PPH, antepartum hemorrhage, hypertensive disease, multiple gestation, parity, prophylactic uterotonics, duration of labor, induction and augmentation of labor, assisted delivery, gestational age, birth canal trauma, placental abruption, and macrosomia.
We will use multivariable logistic regression to examine the association between pain control and episiotomy and the risk of PPH after adjusting for confounding factors. We will describe our causal assumptions using a directed acyclic graph. We will examine the association between the exposures of interest and PPH with odds ratios and 95% confidence intervals. We will estimate odds ratios and 95% CI for the crude association between the exposures of interest and PPH and after controlling for confounding factors. We will check for collinearity using variance inflation factors. Finally, we will examine whether the effect of pain control and episiotomy on the risk of PPH is modified by tranexamic acid treatment. To do this we will conduct stratified analysis and calculate a p-value for heterogeneity using a likelihood ratio test.
- Being tested
- Tranexamic Acid, Placebo
- Keywords
- prevention, postpartum haemorrhage, moderate anaemia, severe anaemia, antifibrinolytic, tranexamic acid, pregnancy, pain, episiotomy
- Medical subject headings
- Anemia, Postpartum Hemorrhage, Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tranexamic AcidDrug
Ampoules and packaging for both arms will be identical in appearance.
PlaceboOther
Also called (Sodium Chloride 0.9%)
Ampoules and packaging for both arms will be identical in appearance.
| Study group | Role | What they receive |
|---|---|---|
| Tranexamic acid | Active comparator | One intravenous injection of tranexamic acid. Total dose 1 gram (10mL) Receives: Drug: Tranexamic Acid |
| Placebo | Placebo comparator | One Injection of the placebo which is 10 mL Sodium Chloride (0.9%) Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postpartum Haemorrhage (cause will be described)
Clinical assessment: This may be an estimated blood loss of more than 500 mL or any blood loss sufficient to compromise haemodynamic stability within 24 hours of delivery. Haemodynamic instability is based on clinical judgement and assessed using clinical signs (low systolic blood pressure, tachycardia, reduced urine output).
Measured: 24 hours after administration of the trial medication or at discharge from hospital, whichever is earlier
Secondary outcomes (19)
Postpartum blood loss
Clinical assessment
Measured: 24 hours after administration of the trial medication or at discharge from hospital, whichever is earlier
Haemoglobin
Haemocue (Point of care test)
Measured: 24 hours after administration of the trial medication or at discharge from hospital, whichever is earlier
Haemodynamic instability
Defined as per protocol
Measured: 24 hours after administration of trial treatment or discharge from hospital, whichever is earlier
Shock index
Heart rate/systolic blood pressure
Measured: 24 hours after administration of trial treatment or discharge from hospital, whichever is earlier
Quality of Life (maternal)
Defined as per protocol
Measured: Day 42 or discharge from hospital, whichever is earlier
Expected side effects of trial medication
nausea, vomiting, diarrhoea
Measured: Day 42 or discharge from hospital, whichever is earlier
Exercise tolerance
6 minute walk test
Measured: Day 42 or discharge from hospital, whichever is earlier
Interventions to control primary postpartum haemorrhage (medical and surgical)
Any of the following: uterotonics, removal of placenta/placenta fragments, intrauterine balloon tamponade, bimanual uterine compression, external aortic compression, non-pneumatic anti-shock garments, uterine artery embolisation, uterine compression suture, hysterectomy and laparotomy to control bleeding
Measured: Day 42 or discharge from hospital, whichever is earlier
Receipt of blood product transfusion
units and type
Measured: Day 42 or discharge of mother from hospital, whichever is earlier
Vascular occlusive events
Any of the following:pulmonary embolism (PE), deep vein thrombosis (DVT), stroke, myocardial infarction
Measured: Day 42 or discharge from hospital, whichever is earlier
Symptoms of anaemia
measured using Quality of life Questionnaire and walk test
Measured: Day 42 or discharge of mother from hospital, whichever is earlier
Organ disfunction
Any of the following: Cardiovascular, Respiratory, Renal, Hepatic, Neurological, Coagulation/ haematologic dysfunction
Measured: Day 42 or discharge from hospital, whichever is earlier
Sepsis
diagnosis is based on the presence of both infection and a systemic inflammatory response syndrome (SIRS). SIRS requires two or more of the following: a) temperature <36°C or >38°C (b) heart rate >90 beats/min (c) respiratory rate >20 breaths/min (d) white blood cell count <4x109/L (<4000/mm³) or >12x109/L (>12,000/mm³)
Measured: Day 42 or discharge from hospital, whichever is earlier
In hospital death
Cause and time of death will be described
Measured: Day 42
Length of hospital stay.
Days
Measured: Day 42 or discharge from hospital, whichever is earlier
Admission to and time spent in higher level facility
High Dependency and/or Intensive Care Units
Measured: Day 42 or discharge from hospital, whichever is earlier
Status of baby/ies
alive or dead
Measured: Day 42 or discharge of mother from hospital, whichever is earlier
Thromboembolic events in breastfed babies
as defined in protocol
Measured: Day 42 or discharge of mother from hospital, whichever is earlier
Adverse events
Any untoward medical occurrence (other than expected complications)
Measured: Day 42
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Mar 2018
- Study start24 Aug 2019
- Primary completion20 Sep 2023
- Study completion29 Oct 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Intrapartum - Moderate and Severe AnaemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- A randomised, double blind, placebo controlled trial among 15,000 women with moderate or severe anaemia having given birth vaginally.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 15,068 participants (actual)
Sponsor and investigators
- Lead sponsor
- London School of Hygiene and Tropical Medicine
- Sponsor type
- University, hospital or other
- Collaborators
- Wellcome Trust, Bill and Melinda Gates Foundation
- Responsible party
- Sponsor
- Investigators
- Ian Roberts, Study chair, Clinical Trials Unit, London School of Hygiene and Tropical MedicineHaleema Shakur-Still, Study chair, Clinical Trials Unit, London School of Hygiene and Tropical MedicineRizwana Chaudhri, Principal investigator, National Coordinating Investigator, Shifa Tameer-e-Millat University, PakistanFolasade A Bello, Principal investigator, National Coordinating Investigator, College of Medicine, University of Ibadan, NigeriaBellington Vwalika, Principal investigator, National Coordinating Investigator, University of Zambia School of Medicine, ZambiaProjestine Muganyizi, Principal investigator, National Coordinating Investigator, Muhimbili University of Health and Allied Sciences, TanzaniaOladapo Olayemi, Principal investigator, National Coordinating Investigator, College of Medicine, University of Ibadan, Nigeria
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03475342
- Sponsor's protocol ID
- WOMAN_2
- Other IDs
- 03475342
- Acronym
- WOMAN-2
- Status last verified
- Apr 2023
- First submitted
- 23 Feb 2018
- Last updated
- 10 Jan 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Data will be shared publicly when all planned analyses are completed by the Woman-2 Trial Collaborators. This will be hosted on freebird.lshtm.ac.uk
Publications
WOMAN-2 Trial Collaborators. The effect of tranexamic acid on postpartum bleeding in women with moderate and severe anaemia (WOMAN-2): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2024 Oct 26;404(10463):1645-1656. doi: 10.1016/S0140-6736(24)01749-5.
PubMed 39461792Larson NJ, Mergoum AM, Dries DJ, Cook A, Blondeau B, Rogers FB. THE ROLE OF TRANEXAMIC ACID IN POSTPARTUM HEMORRHAGE: A NARRATIVE REVIEW. Shock. 2024 Nov 1;62(5):620-627. doi: 10.1097/SHK.0000000000002455. Epub 2024 Aug 20.
PubMed 39162220Collier T, Shakur-Still H, Roberts I, Balogun E, Olayemi O, Bello FA, Chaudhri R, Muganyizi P; WOMAN-2 Trial Collaborators. Tranexamic acid for the prevention of postpartum bleeding in women with anaemia: Statistical analysis plan for the WOMAN-2 trial: an international, randomised, placebo-controlled trial. Gates Open Res. 2023 Aug 3;7:69. doi: 10.12688/gatesopenres.14529.2. eCollection 2023.
PubMed 37664793Brenner A, Roberts I, Balogun E, Bello FA, Chaudhri R, Fleming C, Javaid K, Kayani A, Lubeya MK, Mansukhani R, Olayemi O, Prowse D, Vwalika B, Shakur-Still H. Postpartum haemorrhage in anaemic women: assessing outcome measures for clinical trials. Trials. 2022 Mar 18;23(1):220. doi: 10.1186/s13063-022-06140-z.
PubMed 35303924Ker K, Roberts I, Chaudhri R, Fawole B, Beaumont D, Balogun E, Prowse D, Pepple T, Javaid K, Kayani A, Arulkumaran S, Bates I, Shakur-Still H; WOMAN-2 trial collaborators. Tranexamic acid for the prevention of postpartum bleeding in women with anaemia: study protocol for an international, randomised, double-blind, placebo-controlled trial. Trials. 2018 Dec 29;19(1):712. doi: 10.1186/s13063-018-3081-x.
PubMed 30594227
Study at a glance
From the registry record, last updated by the sponsor on 10 Jan 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Tranexamic Acid for the Prevention of Postpartum Bleeding in Women With Anaemia: an International, Randomised, Double-blind, Placebo Controlled Trial.
- ClinicalTrials.gov ID
- NCT03475342
- Acronym / sponsor ID
- WOMAN-2 / WOMAN_2
- Keywords
- prevention, postpartum haemorrhage, moderate anaemia, severe anaemia, antifibrinolytic, tranexamic acid, pregnancy, pain, episiotomy
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 15,068 participants (actual)
- Lead sponsor
- London School of Hygiene and Tropical MedicineUniversity, hospital or other
- Collaborators
- Wellcome Trust, Bill and Melinda Gates Foundation
- Study start
- 24 Aug 2019 (actual)
- Primary completion
- 20 Sep 2023 (actual)
- Study completion
- 29 Oct 2023 (actual)
- First posted
- 23 Mar 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Postpartum haemorrhage (PPH) is responsible for about 100,000 maternal deaths every year, almost all of which occur in low and middle income countries. When given within three hours of birth, tranexamic acid reduces deaths due to bleeding in women with PPH by almost one third. However, for many women, treatment of PPH is too late to prevent death and severe morbidities. Over one-third of pregnant women in the world are anaemic and many are severely anaemic. We now want to do the WOMAN-2 trial to see if giving tranexamic acid can prevent PPH and other severe outcomes in women with moderate and severe anaemia.
Detailed description
Anaemia is a cause and consequence of PPH. A cohort study in Assam, India found that women with moderate or severe anaemia had a greatly increased risk of PPH. Women with moderate anaemia had a 50% increased risk, whereas those with severe anaemia had a ten-fold increased risk of PPH. Anaemic women may be more susceptible to uterine atony due to impaired oxygen transport to the uterus. Anaemic women experience worse outcomes after PPH. An international survey of 275,000 women found that severe maternal outcomes after PPH were nearly three times more common in anaemic than in non-anaemic women. Even moderate bleeding can be life threatening in anaemic women. Excessive bleeding after childbirth worsens maternal anaemia, resulting in a vicious circle of bleeding and adverse outcomes. Fatigue due to anaemia severely limits a mothers' wellbeing and her ability to care for her children. Despite efforts to prevent anaemia, many women labour with perilously low haemoglobin levels
Tranexamic acid (TXA) inhibits fibrinolysis by blocking the lysine binding sites on plasminogen. TXA reduces surgical bleeding and death due to bleeding in trauma patients. The WOMAN trial assessed the effects of TXA in 20,060 women with PPH. When given within three hours of birth, TXA reduced death due to bleeding by nearly one-third (RR=0.69, 95% CI 0.52 to 0.91, p=0.008). However, for many women, treatment is too late to prevent death from PPH. Most PPH deaths occur in the first hours after giving birth and women with anaemia are at greatly increased risk. Whilst there have been some trials of TXA for the prevention of PPH, most have serious flaws and none collected data on maternal health and wellbeing. There is currently no reliable evidence about the effectiveness and safety of TXA for preventing PPH.
The WOMAN-2 trial will determine reliably the effects of TXA in anaemic women who give birth vaginally.
We will also conduct a pre-planned cohort analysis of data from the WOMAN-2 trial to assess the effect of pain control and episiotomy on the risk of post-partum haemorrhage. Adrenaline is a potent stimulus for fibrinolysis. Adrenaline causes the release of tissue plasminogen activator (TPA) from the endothelium. In trauma victims, high adrenaline levels are associated with increased fibrinolysis, decreased clot strength and increased deaths due to bleeding. Childbirth is intensely painful and maternal adrenaline levels are two to six times higher during labour. Maternal adrenaline concentrations peak in the second and third stages of labour but then rapidly return to normal after birth. Pain control can reduce the maternal catecholamine response. We hypothesize that painful procedures such as episiotomy will significantly increase the risk of postpartum haemorrhage and that pain control will reduce the risk of PPH.
The exposures of interest are the presence or absence of pain control during labour and delivery and whether episiotomy was conducted prior to birth. Pain control will be categorised as present or absent but the type of pain control administered during labour will also be described and examined. The types of pain control recorded in the study are epidural, opioids, 'other', or a combination of opioids and other pain control. For the multivariable regression analysis, the pain control variable was converted into a binary variable indicating whether a participant received any pain control or not. Episiotomy will be categorised as present or absent according to the CRF. The main outcome variable will be a clinical diagnosis of PPH (binary: yes/no), defined as an estimated blood loss of more than 500 mL or any blood loss sufficient to compromise haemodynamic stability within 24 hours. Potential confounding factors will include maternal age, BMI, anaemia, history of PPH, antepartum hemorrhage, hypertensive disease, multiple gestation, parity, prophylactic uterotonics, duration of labor, induction and augmentation of labor, assisted delivery, gestational age, birth canal trauma, placental abruption, and macrosomia.
We will use multivariable logistic regression to examine the association between pain control and episiotomy and the risk of PPH after adjusting for confounding factors. We will describe our causal assumptions using a directed acyclic graph. We will examine the association between the exposures of interest and PPH with odds ratios and 95% confidence intervals. We will estimate odds ratios and 95% CI for the crude association between the exposures of interest and PPH and after controlling for confounding factors. We will check for collinearity using variance inflation factors. Finally, we will examine whether the effect of pain control and episiotomy on the risk of PPH is modified by tranexamic acid treatment. To do this we will conduct stratified analysis and calculate a p-value for heterogeneity using a likelihood ratio test.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- A randomised, double blind, placebo controlled trial among 15,000 women with moderate or severe anaemia having given birth vaginally.
| Arm | Type | Receives |
|---|---|---|
| Tranexamic acid | Active comparator | Drug: Tranexamic AcidOne intravenous injection of tranexamic acid. Total dose 1 gram (10mL) |
| Placebo | Placebo comparator | Other: PlaceboOne Injection of the placebo which is 10 mL Sodium Chloride (0.9%) |
Who may qualify
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- Women with moderate or severe anaemia (haemoglobin level <100 g/L or packed cell volume <30%) after giving birth vaginally where the responsible clinician is substantially uncertain whether to use TXA
Key exclusion criteria (3 listed)
- Women who are not legally adult (<18 years) and not accompanied by a guardian
- Women with a known allergy to tranexamic acid or its excipients
- Women who experience postpartum haemorrhage before the umbilical cord is cut or clamped.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tranexamic AcidAmpoules and packaging for both arms will be identical in appearance. | Drug | Tranexamic acid |
| PlaceboAlso: (Sodium Chloride 0.9%)Ampoules and packaging for both arms will be identical in appearance. | Other | Placebo |
Primary outcome
Postpartum Haemorrhage (cause will be described)
Time frame: 24 hours after administration of the trial medication or at discharge from hospital, whichever is earlier
Clinical assessment: This may be an estimated blood loss of more than 500 mL or any blood loss sufficient to compromise haemodynamic stability within 24 hours of delivery. Haemodynamic instability is based on clinical judgement and assessed using clinical signs (low systolic blood pressure, tachycardia, reduced urine output).
19 secondary outcomes
Postpartum blood loss
Time frame: 24 hours after administration of the trial medication or at discharge from hospital, whichever is earlier
Haemoglobin
Time frame: 24 hours after administration of the trial medication or at discharge from hospital, whichever is earlier
Haemodynamic instability
Time frame: 24 hours after administration of trial treatment or discharge from hospital, whichever is earlier
Shock index
Time frame: 24 hours after administration of trial treatment or discharge from hospital, whichever is earlier
Quality of Life (maternal)
Time frame: Day 42 or discharge from hospital, whichever is earlier
Expected side effects of trial medication
Time frame: Day 42 or discharge from hospital, whichever is earlier
Exercise tolerance
Time frame: Day 42 or discharge from hospital, whichever is earlier
Interventions to control primary postpartum haemorrhage (medical and surgical)
Time frame: Day 42 or discharge from hospital, whichever is earlier
Receipt of blood product transfusion
Time frame: Day 42 or discharge of mother from hospital, whichever is earlier
Vascular occlusive events
Time frame: Day 42 or discharge from hospital, whichever is earlier
Symptoms of anaemia
Time frame: Day 42 or discharge of mother from hospital, whichever is earlier
Organ disfunction
Time frame: Day 42 or discharge from hospital, whichever is earlier
Sepsis
Time frame: Day 42 or discharge from hospital, whichever is earlier
In hospital death
Time frame: Day 42
Length of hospital stay.
Time frame: Day 42 or discharge from hospital, whichever is earlier
Admission to and time spent in higher level facility
Time frame: Day 42 or discharge from hospital, whichever is earlier
Status of baby/ies
Time frame: Day 42 or discharge of mother from hospital, whichever is earlier
Thromboembolic events in breastfed babies
Time frame: Day 42 or discharge of mother from hospital, whichever is earlier
Adverse events
Time frame: Day 42
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jan 2024.
- Derived from this study: PubMed 39461792WOMAN-2 Trial Collaborators. The effect of tranexamic acid on postpartum bleeding in women with moderate and severe anaemia (WOMAN-2): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2024 Oct 26;404(10463):1645-1656. doi: 10.1016/S0140-6736(24)01749-5.
- Derived from this study: PubMed 39162220Larson NJ, Mergoum AM, Dries DJ, Cook A, Blondeau B, Rogers FB. THE ROLE OF TRANEXAMIC ACID IN POSTPARTUM HEMORRHAGE: A NARRATIVE REVIEW. Shock. 2024 Nov 1;62(5):620-627. doi: 10.1097/SHK.0000000000002455. Epub 2024 Aug 20.
- Derived from this study: PubMed 37664793Collier T, Shakur-Still H, Roberts I, Balogun E, Olayemi O, Bello FA, Chaudhri R, Muganyizi P; WOMAN-2 Trial Collaborators. Tranexamic acid for the prevention of postpartum bleeding in women with anaemia: Statistical analysis plan for the WOMAN-2 trial: an international, randomised, placebo-controlled trial. Gates Open Res. 2023 Aug 3;7:69. doi: 10.12688/gatesopenres.14529.2. eCollection 2023.
- Derived from this study: PubMed 35303924Brenner A, Roberts I, Balogun E, Bello FA, Chaudhri R, Fleming C, Javaid K, Kayani A, Lubeya MK, Mansukhani R, Olayemi O, Prowse D, Vwalika B, Shakur-Still H. Postpartum haemorrhage in anaemic women: assessing outcome measures for clinical trials. Trials. 2022 Mar 18;23(1):220. doi: 10.1186/s13063-022-06140-z.
- Derived from this study: PubMed 30594227Ker K, Roberts I, Chaudhri R, Fawole B, Beaumont D, Balogun E, Prowse D, Pepple T, Javaid K, Kayani A, Arulkumaran S, Bates I, Shakur-Still H; WOMAN-2 trial collaborators. Tranexamic acid for the prevention of postpartum bleeding in women with anaemia: study protocol for an international, randomised, double-blind, placebo-controlled trial. Trials. 2018 Dec 29;19(1):712. doi: 10.1186/s13063-018-3081-x.
- Individual participant dataSharing planned: Yes. Data will be shared publicly when all planned analyses are completed by the Woman-2 Trial Collaborators. This will be hosted on freebird.lshtm.ac.uk
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ian Roberts study chair
Clinical Trials Unit, London School of Hygiene and Tropical Medicine
Haleema Shakur-Still study chair
Clinical Trials Unit, London School of Hygiene and Tropical Medicine
Rizwana Chaudhri principal investigator
National Coordinating Investigator, Shifa Tameer-e-Millat University, Pakistan
41 sites in 4 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Tranexamic Acid in people with Intrapartum - Moderate and Severe Anaemia, run by London School of Hygiene and Tropical Medicine at 41 sites in 4 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 41 sites in Pakistan, Tanzania, Nigeria, Zambia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postpartum Haemorrhage (cause will be described) (time frame: 24 hours after administration of the trial medication or at discharge from hospital, whichever is earlier). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03475342, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jan 2024; AzTrials last refreshed its copy on 29 Oct 2026.